Overexpression of EGFR has been reported in >90% of pancreatic tumours and has also been shown to correlate with poorer prognosis.27 Despite these observations providing a clear rationale for the use of CTX in PaCa, it has so far failed to impart a meaningful clinical benefit in this tumour setting when combined with other frontline agents,28–30 most likely because of the concomitant high frequency of KRAS mutations in this disease. This evidence concerns the gene KRAS and pancreatic neoplasm.